News

Home>News
News2020-07-17T11:41:26-04:00
Nov 252020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

November 25th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV.  Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman detailed some of the most recent developments in Halberd’s top priority research: to develop products which should facilitate diagnostic, prevention ...

Nov 192020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

November 19th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood.  By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects than with more conventional treatment regimens. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio ...

Nov 162020

Halberd Corp. CEO Interviewed on Money TV; Discusses New Fluorescent Covid-19 Antibody

November 16th, 2020|Categories: Featured, Investor News, News|

Mr. Hartman discusses advantages over existing antibodies. Jackson Center, PA, November 16, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided information on Halberd’s new patent pending Covid-19 fluorescent antibody.  This should allow for rapid detection of the virus in infected patients and provide up-to-the-minute status of whether or not an individual has contracted the ...

Nov 122020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

November 12th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University.  The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 antigens.  Halberd is working to develop this fluorescent antibody into a rapid test mechanism for detecting Covid-19 antigens from saliva ...

Nov 92020

Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19

November 9th, 2020|Categories: Featured, Investor News, News|

Jackson Center, PA, November 9, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a Covid-19 provisional patent on an enhanced nasal spray.  The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies.  This application builds on, and is an improvement to an earlier provisional patent application, “Nasal Spray to Prevent the Transmission of Covid-19 Between Humans.” Multiple medical ...

Nov 52020

Halberd Corp. Develops Second Covid-19 Antibody for Enhanced Nasal Spray and Doubles Performance of New Class of Antibody

November 5th, 2020|Categories: Featured, Investor News, News|

Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray.  Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a key functional parameter. Dr. Mitchell S. Felder, a Halberd consultant, filed a provisional patent application for a nasal spray utilizing ...

Go to Top